glp-1 adoption Receptor Agonist Market Forecast Report, 2033 Impact of GLP-1 Drug Adoption

Another phase 2 RCT studying semglutide 2.4 mg vs placebo in patients with compensated NASH cirrhosis did not show any statistically significant difference in NASH resolution or improvement in liver fibrosis between the groups

[11] Any future GLP-1 patch would require robust clinical trial evidence demonstrating efficacy, safety, and pharmacokinetic profiles comparable to existing injectable formulations before regulatory approval could be granted

931 of 06-06-2022) - project n

Phase 2 trials used once-weekly subcutaneous injections ranging from 1 mg to 12 mg, with higher doses associated with greater weight reduction but more gastrointestinal side effects

The other half

Human thyroid C-cells have very few GLP-1 receptors, and large clinical trials have not shown an increased risk compared to placebo